APO Research
Talk to an analyst

APO RESEARCH · REPORT

Gastrointestinal Therapeutics and Diagnostics

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Gastrointestinal Therapeutics and Diagnostics Market Analysis and Forecast 2026-2032

21 December 2025198 pages

Choose your research edition.

Industry ResearchGastrointestinal Therapeutics and Diagnostics Industry Research Report 2026111 pages · $2,950 USDIndustry Growth & TrendsGlobal Gastrointestinal Therapeutics and Diagnostics Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal Gastrointestinal Therapeutics and Diagnostics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Gastrointestinal Therapeutics and Diagnostics Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Gastrointestinal Therapeutics and Diagnostics Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Gastrointestinal Therapeutics and Diagnostics market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Gastrointestinal Therapeutics and Diagnostics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Gastrointestinal Therapeutics and Diagnostics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Gastrointestinal Therapeutics and Diagnostics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Gastrointestinal Therapeutics and Diagnostics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Gastrointestinal Therapeutics and Diagnostics include Takeda Pharmaceutical Company, Eisai, Johnson & Johnson, AstraZeneca, Salix Pharmaceuticals and Abbott Laboratories, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Gastrointestinal Therapeutics and Diagnostics, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Gastrointestinal Therapeutics and Diagnostics, also provides the revenue of main regions and countries. Of the upcoming market potential for Gastrointestinal Therapeutics and Diagnostics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Gastrointestinal Therapeutics and Diagnostics revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Gastrointestinal Therapeutics and Diagnostics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Gastrointestinal Therapeutics and Diagnostics revenue, projected growth trends, production technology, application and end-user industry.

Gastrointestinal Therapeutics and Diagnostics Segment by Company

Takeda Pharmaceutical Company

Eisai

Johnson & Johnson

AstraZeneca

Salix Pharmaceuticals

Abbott Laboratories

Gastrointestinal Therapeutics and Diagnostics Segment by Type

Diagnostics

Therapeutics

Gastrointestinal Therapeutics and Diagnostics Segment by Application

Peptic Ulcer Disease (PUD)

GI Bleeding

Gastroenteritis

Irritable Bowel Syndrome

Others

Gastrointestinal Therapeutics and Diagnostics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gastrointestinal Therapeutics and Diagnostics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Gastrointestinal Therapeutics and Diagnostics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gastrointestinal Therapeutics and Diagnostics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Gastrointestinal Therapeutics and Diagnostics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Gastrointestinal Therapeutics and Diagnostics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Gastrointestinal Therapeutics and Diagnostics revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Gastrointestinal Therapeutics and Diagnostics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Diagnostics Major Player Table 3. Therapeutics Major Player Table 4. Global Gastrointestinal Therapeutics and Diagnostics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Peptic Ulcer Disease (PUD) Major Player Table 6. GI Bleeding Major Player Table 7. Gastroenteritis Major Player Table 8. Irritable Bowel Syndrome Major Player Table 9. Others Major Player Table 10. Gastrointestinal Therapeutics and Diagnostics Industry Trends Table 11. Gastrointestinal Therapeutics and Diagnostics Industry Drivers Table 12. Gastrointestinal Therapeutics and Diagnostics Industry Opportunities and Challenges Table 13. Gastrointestinal Therapeutics and Diagnostics Industry Restraints Table 14. Global Gastrointestinal Therapeutics and Diagnostics Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Gastrointestinal Therapeutics and Diagnostics Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Gastrointestinal Therapeutics and Diagnostics Market Share by Region (2021-2026) Table 17. Global Gastrointestinal Therapeutics and Diagnostics Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Gastrointestinal Therapeutics and Diagnostics Market Share by Region (2027-2032) Table 19. Global Gastrointestinal Therapeutics and Diagnostics Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Gastrointestinal Therapeutics and Diagnostics Revenue Market Share by Players (2021-2026) Table 21. Global Gastrointestinal Therapeutics and Diagnostics Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Gastrointestinal Therapeutics and Diagnostics Key Players Headquarters & Area Served Table 23. Global Gastrointestinal Therapeutics and Diagnostics Players, Product Type & Application Table 24. Global Gastrointestinal Therapeutics and Diagnostics Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Gastrointestinal Therapeutics and Diagnostics by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Gastrointestinal Therapeutics and Diagnostics Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Gastrointestinal Therapeutics and Diagnostics Revenue Market Share by Type (2021-2026) Table 31. Global Gastrointestinal Therapeutics and Diagnostics Revenue Market Share by Type (2027-2032) Table 32. Global Gastrointestinal Therapeutics and Diagnostics Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Gastrointestinal Therapeutics and Diagnostics Revenue Market Share by Application (2021-2026) Table 36. Global Gastrointestinal Therapeutics and Diagnostics Revenue Market Share by Application (2027-2032) Table 37. Takeda Pharmaceutical Company Company Information Table 38. Takeda Pharmaceutical Company Business Overview Table 39. Takeda Pharmaceutical Company Gastrointestinal Therapeutics and Diagnostics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Takeda Pharmaceutical Company Gastrointestinal Therapeutics and Diagnostics Product Portfolio Table 41. Takeda Pharmaceutical Company Recent Development Table 42. Eisai Company Information Table 43. Eisai Business Overview Table 44. Eisai Gastrointestinal Therapeutics and Diagnostics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Eisai Gastrointestinal Therapeutics and Diagnostics Product Portfolio Table 46. Eisai Recent Development Table 47. Johnson & Johnson Company Information Table 48. Johnson & Johnson Business Overview Table 49. Johnson & Johnson Gastrointestinal Therapeutics and Diagnostics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Johnson & Johnson Gastrointestinal Therapeutics and Diagnostics Product Portfolio Table 51. Johnson & Johnson Recent Development Table 52. AstraZeneca Company Information Table 53. AstraZeneca Business Overview Table 54. AstraZeneca Gastrointestinal Therapeutics and Diagnostics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. AstraZeneca Gastrointestinal Therapeutics and Diagnostics Product Portfolio Table 56. AstraZeneca Recent Development Table 57. Salix Pharmaceuticals Company Information Table 58. Salix Pharmaceuticals Business Overview Table 59. Salix Pharmaceuticals Gastrointestinal Therapeutics and Diagnostics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Salix Pharmaceuticals Gastrointestinal Therapeutics and Diagnostics Product Portfolio Table 61. Salix Pharmaceuticals Recent Development Table 62. Abbott Laboratories Company Information Table 63. Abbott Laboratories Business Overview Table 64. Abbott Laboratories Gastrointestinal Therapeutics and Diagnostics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Abbott Laboratories Gastrointestinal Therapeutics and Diagnostics Product Portfolio Table 66. Abbott Laboratories Recent Development Table 67. North America Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2021-2026) & (US$ Million) Table 68. North America Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2027-2032) & (US$ Million) Table 69. North America Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2021-2026) & (US$ Million) Table 70. North America Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2027-2032) & (US$ Million) Table 71. North America Gastrointestinal Therapeutics and Diagnostics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 72. North America Gastrointestinal Therapeutics and Diagnostics Revenue by Country (2021-2026) & (US$ Million) Table 73. North America Gastrointestinal Therapeutics and Diagnostics Revenue by Country (US$ Million) & (2027-2032) Table 74. Europe Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2021-2026) & (US$ Million) Table 75. Europe Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2027-2032) & (US$ Million) Table 76. Europe Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2021-2026) & (US$ Million) Table 77. Europe Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2027-2032) & (US$ Million) Table 78. Europe Gastrointestinal Therapeutics and Diagnostics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 79. Europe Gastrointestinal Therapeutics and Diagnostics Revenue by Country (2021-2026) & (US$ Million) Table 80. Europe Gastrointestinal Therapeutics and Diagnostics Revenue by Country (US$ Million) & (2027-2032) Table 81. China Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2021-2026) & (US$ Million) Table 82. China Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2027-2032) & (US$ Million) Table 83. China Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2021-2026) & (US$ Million) Table 84. China Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2027-2032) & (US$ Million) Table 85. Asia Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2021-2026) & (US$ Million) Table 86. Asia Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2027-2032) & (US$ Million) Table 87. Asia Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2021-2026) & (US$ Million) Table 88. Asia Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2027-2032) & (US$ Million) Table 89. Asia Gastrointestinal Therapeutics and Diagnostics Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 90. Asia Gastrointestinal Therapeutics and Diagnostics Revenue by Region (US$ Million) & (2021-2026) Table 91. Asia Gastrointestinal Therapeutics and Diagnostics Revenue by Region (US$ Million) & (2027-2032) Table 92. SAMEA Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2021-2026) & (US$ Million) Table 93. SAMEA Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2027-2032) & (US$ Million) Table 94. SAMEA Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2021-2026) & (US$ Million) Table 95. SAMEA Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2027-2032) & (US$ Million) Table 96. SAMEA Gastrointestinal Therapeutics and Diagnostics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 97. SAMEA Gastrointestinal Therapeutics and Diagnostics Revenue by Country (2021-2026) & (US$ Million) Table 98. SAMEA Gastrointestinal Therapeutics and Diagnostics Revenue by Country (US$ Million) & (2027-2032) Table 99. Research Programs/Design for This Report Table 100. Authors List of This Report Table 101. Secondary Sources Table 102. Primary Sources List of Figures Figure 1. Gastrointestinal Therapeutics and Diagnostics Image Figure 2. Global Gastrointestinal Therapeutics and Diagnostics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Gastrointestinal Therapeutics and Diagnostics Market Size Share 2021 VS 2025 VS 2032 Figure 4. Diagnostics Image Figure 5. Therapeutics Image Figure 6. Global Gastrointestinal Therapeutics and Diagnostics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Gastrointestinal Therapeutics and Diagnostics Market Size Share 2021 VS 2025 VS 2032 Figure 8. Peptic Ulcer Disease (PUD) Image Figure 9. GI Bleeding Image Figure 10. Gastroenteritis Image Figure 11. Irritable Bowel Syndrome Image Figure 12. Others Image Figure 13. Global Gastrointestinal Therapeutics and Diagnostics Market Size (US$ Million) & (2021-2032) Figure 14. Global Gastrointestinal Therapeutics and Diagnostics Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Gastrointestinal Therapeutics and Diagnostics Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Gastrointestinal Therapeutics and Diagnostics Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Gastrointestinal Therapeutics and Diagnostics Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Gastrointestinal Therapeutics and Diagnostics Revenue Market Share by Type (2021-2032) Figure 21. Global Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Gastrointestinal Therapeutics and Diagnostics Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Gastrointestinal Therapeutics and Diagnostics Revenue Market Share by Application (2021-2032) Figure 24. North America Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Gastrointestinal Therapeutics and Diagnostics Revenue Share by Type (2021-2032) Figure 26. North America Gastrointestinal Therapeutics and Diagnostics Revenue Share by Application (2021-2032) Figure 27. North America Gastrointestinal Therapeutics and Diagnostics Revenue Share by Country (2021-2032) Figure 28. United States Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Gastrointestinal Therapeutics and Diagnostics Revenue Share by Type (2021-2032) Figure 33. Europe Gastrointestinal Therapeutics and Diagnostics Revenue Share by Application (2021-2032) Figure 34. Europe Gastrointestinal Therapeutics and Diagnostics Revenue Share by Country (2021-2032) Figure 35. Germany Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Gastrointestinal Therapeutics and Diagnostics Revenue Share by Type (2021-2032) Figure 45. China Gastrointestinal Therapeutics and Diagnostics Revenue Share by Application (2021-2032) Figure 46. Asia Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Gastrointestinal Therapeutics and Diagnostics Revenue Share by Type (2021-2032) Figure 48. Asia Gastrointestinal Therapeutics and Diagnostics Revenue Share by Application (2021-2032) Figure 49. Asia Gastrointestinal Therapeutics and Diagnostics Revenue Share by Region (2021-2032) Figure 50. Japan Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Gastrointestinal Therapeutics and Diagnostics Revenue Share by Type (2021-2032) Figure 58. SAMEA Gastrointestinal Therapeutics and Diagnostics Revenue Share by Application (2021-2032) Figure 59. SAMEA Gastrointestinal Therapeutics and Diagnostics Revenue Share by Country (2021-2032) Figure 60. Brazil Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Diagnostics
  • Therapeutics
Applications
  • Peptic Ulcer Disease (PUD)
  • GI Bleeding
  • Gastroenteritis
  • Irritable Bowel Syndrome
  • Others
Companies covered
  • Takeda Pharmaceutical Company
  • Eisai
  • Johnson & Johnson
  • AstraZeneca
  • Salix Pharmaceuticals
  • Abbott Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Gastrointestinal Therapeutics and Diagnostics Market by Type
  3. 1.2.1 Global Gastrointestinal Therapeutics and Diagnostics Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Diagnostics
  5. 1.2.3 Therapeutics
  6. 1.3 Gastrointestinal Therapeutics and Diagnostics Market by Application
  7. 1.3.1 Global Gastrointestinal Therapeutics and Diagnostics Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Peptic Ulcer Disease (PUD)
  9. 1.3.3 GI Bleeding
  10. 1.3.4 Gastroenteritis
  11. 1.3.5 Irritable Bowel Syndrome
  12. 1.3.6 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Gastrointestinal Therapeutics and Diagnostics Market Dynamics
  1. 2.1 Gastrointestinal Therapeutics and Diagnostics Industry Trends
  2. 2.2 Gastrointestinal Therapeutics and Diagnostics Industry Drivers
  3. 2.3 Gastrointestinal Therapeutics and Diagnostics Industry Opportunities and Challenges
  4. 2.4 Gastrointestinal Therapeutics and Diagnostics Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Gastrointestinal Therapeutics and Diagnostics Market Perspective (2021-2032)
  2. 3.2 Global Gastrointestinal Therapeutics and Diagnostics Growth Trends by Region
  3. 3.2.1 Global Gastrointestinal Therapeutics and Diagnostics Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Gastrointestinal Therapeutics and Diagnostics Market Size by Region (2021-2026)
  5. 3.2.3 Global Gastrointestinal Therapeutics and Diagnostics Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Gastrointestinal Therapeutics and Diagnostics Revenue by Players
  2. 4.1.1 Global Gastrointestinal Therapeutics and Diagnostics Revenue by Players (2021-2026)
  3. 4.1.2 Global Gastrointestinal Therapeutics and Diagnostics Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Gastrointestinal Therapeutics and Diagnostics Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Gastrointestinal Therapeutics and Diagnostics Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Gastrointestinal Therapeutics and Diagnostics Key Players Headquarters & Area Served
  7. 4.4 Global Gastrointestinal Therapeutics and Diagnostics Players, Product Type & Application
  8. 4.5 Global Gastrointestinal Therapeutics and Diagnostics Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Gastrointestinal Therapeutics and Diagnostics Market CR5 and HHI
  11. 4.6.3 2025 Gastrointestinal Therapeutics and Diagnostics Tier 1, Tier 2, and Tier 3
5 Gastrointestinal Therapeutics and Diagnostics Market Size by Type
  1. 5.1 Global Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2021-2032)
  3. 5.3 Global Gastrointestinal Therapeutics and Diagnostics Revenue Market Share by Type (2021-2032)
6 Gastrointestinal Therapeutics and Diagnostics Market Size by Application
  1. 6.1 Global Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2021-2032)
  3. 6.3 Global Gastrointestinal Therapeutics and Diagnostics Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Takeda Pharmaceutical Company
  2. 7.1.1 Takeda Pharmaceutical Company Company Information
  3. 7.1.2 Takeda Pharmaceutical Company Business Overview
  4. 7.1.3 Takeda Pharmaceutical Company Gastrointestinal Therapeutics and Diagnostics Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Takeda Pharmaceutical Company Gastrointestinal Therapeutics and Diagnostics Product Portfolio
  6. 7.1.5 Takeda Pharmaceutical Company Recent Developments
  7. 7.2 Eisai
  8. 7.2.1 Eisai Company Information
  9. 7.2.2 Eisai Business Overview
  10. 7.2.3 Eisai Gastrointestinal Therapeutics and Diagnostics Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Eisai Gastrointestinal Therapeutics and Diagnostics Product Portfolio
  12. 7.2.5 Eisai Recent Developments
  13. 7.3 Johnson & Johnson
  14. 7.3.1 Johnson & Johnson Company Information
  15. 7.3.2 Johnson & Johnson Business Overview
  16. 7.3.3 Johnson & Johnson Gastrointestinal Therapeutics and Diagnostics Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Johnson & Johnson Gastrointestinal Therapeutics and Diagnostics Product Portfolio
  18. 7.3.5 Johnson & Johnson Recent Developments
  19. 7.4 AstraZeneca
  20. 7.4.1 AstraZeneca Company Information
  21. 7.4.2 AstraZeneca Business Overview
  22. 7.4.3 AstraZeneca Gastrointestinal Therapeutics and Diagnostics Revenue and Gross Margin (2021-2026)
  23. 7.4.4 AstraZeneca Gastrointestinal Therapeutics and Diagnostics Product Portfolio
  24. 7.4.5 AstraZeneca Recent Developments
  25. 7.5 Salix Pharmaceuticals
  26. 7.5.1 Salix Pharmaceuticals Company Information
  27. 7.5.2 Salix Pharmaceuticals Business Overview
  28. 7.5.3 Salix Pharmaceuticals Gastrointestinal Therapeutics and Diagnostics Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Salix Pharmaceuticals Gastrointestinal Therapeutics and Diagnostics Product Portfolio
  30. 7.5.5 Salix Pharmaceuticals Recent Developments
  31. 7.6 Abbott Laboratories
  32. 7.6.1 Abbott Laboratories Company Information
  33. 7.6.2 Abbott Laboratories Business Overview
  34. 7.6.3 Abbott Laboratories Gastrointestinal Therapeutics and Diagnostics Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Abbott Laboratories Gastrointestinal Therapeutics and Diagnostics Product Portfolio
  36. 7.6.5 Abbott Laboratories Recent Developments
8 North America
  1. 8.1 North America Gastrointestinal Therapeutics and Diagnostics Revenue (2021-2032)
  2. 8.2 North America Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2021-2032)
  3. 8.2.1 North America Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2021-2026)
  4. 8.2.2 North America Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2027-2032)
  5. 8.3 North America Gastrointestinal Therapeutics and Diagnostics Revenue Share by Type (2021-2032)
  6. 8.4 North America Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2021-2032)
  7. 8.4.1 North America Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2021-2026)
  8. 8.4.2 North America Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2027-2032)
  9. 8.5 North America Gastrointestinal Therapeutics and Diagnostics Revenue Share by Application (2021-2032)
  10. 8.6 North America Gastrointestinal Therapeutics and Diagnostics Revenue by Country
  11. 8.6.1 North America Gastrointestinal Therapeutics and Diagnostics Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Gastrointestinal Therapeutics and Diagnostics Revenue by Country (2021-2026)
  13. 8.6.3 North America Gastrointestinal Therapeutics and Diagnostics Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Gastrointestinal Therapeutics and Diagnostics Revenue (2021-2032)
  2. 9.2 Europe Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2021-2032)
  3. 9.2.1 Europe Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2021-2026)
  4. 9.2.2 Europe Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2027-2032)
  5. 9.3 Europe Gastrointestinal Therapeutics and Diagnostics Revenue Share by Type (2021-2032)
  6. 9.4 Europe Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2021-2032)
  7. 9.4.1 Europe Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2021-2026)
  8. 9.4.2 Europe Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2027-2032)
  9. 9.5 Europe Gastrointestinal Therapeutics and Diagnostics Revenue Share by Application (2021-2032)
  10. 9.6 Europe Gastrointestinal Therapeutics and Diagnostics Revenue by Country
  11. 9.6.1 Europe Gastrointestinal Therapeutics and Diagnostics Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Gastrointestinal Therapeutics and Diagnostics Revenue by Country (2021-2026)
  13. 9.6.3 Europe Gastrointestinal Therapeutics and Diagnostics Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Gastrointestinal Therapeutics and Diagnostics Revenue (2021-2032)
  2. 10.2 China Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2021-2032)
  3. 10.2.1 China Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2021-2026)
  4. 10.2.2 China Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2027-2032)
  5. 10.3 China Gastrointestinal Therapeutics and Diagnostics Revenue Share by Type (2021-2032)
  6. 10.4 China Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2021-2032)
  7. 10.4.1 China Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2021-2026)
  8. 10.4.2 China Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2027-2032)
  9. 10.5 China Gastrointestinal Therapeutics and Diagnostics Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Gastrointestinal Therapeutics and Diagnostics Revenue (2021-2032)
  2. 11.2 Asia Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2021-2032)
  3. 11.2.1 Asia Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2021-2026)
  4. 11.2.2 Asia Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2027-2032)
  5. 11.3 Asia Gastrointestinal Therapeutics and Diagnostics Revenue Share by Type (2021-2032)
  6. 11.4 Asia Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2021-2032)
  7. 11.4.1 Asia Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2021-2026)
  8. 11.4.2 Asia Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2027-2032)
  9. 11.5 Asia Gastrointestinal Therapeutics and Diagnostics Revenue Share by Application (2021-2032)
  10. 11.6 Asia Gastrointestinal Therapeutics and Diagnostics Revenue by Country
  11. 11.6.1 Asia Gastrointestinal Therapeutics and Diagnostics Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Gastrointestinal Therapeutics and Diagnostics Revenue by Country (2021-2026)
  13. 11.6.3 Asia Gastrointestinal Therapeutics and Diagnostics Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Gastrointestinal Therapeutics and Diagnostics Revenue (2021-2032)
  2. 12.2 SAMEA Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2027-2032)
  5. 12.3 SAMEA Gastrointestinal Therapeutics and Diagnostics Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2027-2032)
  9. 12.5 SAMEA Gastrointestinal Therapeutics and Diagnostics Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Gastrointestinal Therapeutics and Diagnostics Revenue by Country
  11. 12.6.1 SAMEA Gastrointestinal Therapeutics and Diagnostics Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Gastrointestinal Therapeutics and Diagnostics Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Gastrointestinal Therapeutics and Diagnostics Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst